Literature DB >> 28393211

Search for useful biomarkers in hepatocellular carcinoma, tumor factors and background liver factors (Review).

Dai Shimizu1, Yoshikuni Inokawa1, Fuminori Sonohara1, Kenichi Inaoka1, Shuji Nomoto1.   

Abstract

Hepatocarcinogenesis is a complex and multistep process that involves the accumulation of genetic and epigenetic alterations in regulatory genes. To understand the development of hepatocellular carcinoma (HCC), current research has utilized improved array technologies. The identification of cancer-related molecules could lead to the development of novel molecular targets for treatment and biomarkers for predicting prognosis. However, prognostic prediction is insufficient when considering only tumor factors, since hepatocarcinogenesis is also greatly influenced by the status of the background liver. Clinical background liver factors, such as the presence of chronic active hepatitis or cirrhosis, are well known as risk factors for developing HCC. In contrast, genetic or epigenetic background liver factors remain unknown, albeit those are important to understand the developing process of HCC. Investigating background liver factors could contribute to the development of carcinogenic markers of HCC and to the prevention of the development of HCC. In the present study, we review the currently identified tumor factors and background liver factors from a molecular biological viewpoint and also introduce our combination array analysis.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28393211     DOI: 10.3892/or.2017.5541

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  6 in total

1.  GTSF1 gene may serve as a novel potential diagnostic biomarker for liver cancer.

Authors:  De-Yong Gao; Yun Ling; Xiao-Li Lou; Ying-Ying Wang; Liang-Ming Liu
Journal:  Oncol Lett       Date:  2017-12-27       Impact factor: 2.967

2.  Yes-associated protein: A novel molecular target for the diagnosis, treatment and prognosis of hepatocellular carcinoma.

Authors:  Liang Shan; Hongyuan Jiang; Lifang Ma; Yongchun Yu
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

3.  Knockdown of RRS1 by lentiviral-mediated RNAi promotes apoptosis and suppresses proliferation of human hepatocellular carcinoma cells.

Authors:  Jitao Wang; Zhi Li; Changzeng Zuo; Qingfan Xie; Hui Li; Junhong Jia; Zhongguang Zhen; Ruizhao Qi; Zhiwei Li; Dengxiang Liu; Baijun Sun
Journal:  Oncol Rep       Date:  2017-08-14       Impact factor: 3.906

4.  Anticancer Effects of Gleditsia sinensis Extract in Rats Transplanted With Hepatocellular Carcinoma Cells.

Authors:  Yue Cai; Chizhi Zhang; Lei Zhan; Liangbin Cheng; Dingbo Lu; Xiaodong Wang; Hanlin Xu; Shuxue Wang; Deng Wu; Lianguo Ruan
Journal:  Oncol Res       Date:  2019-04-02       Impact factor: 5.574

5.  Identification of novel lactate metabolism signatures and molecular subtypes for prognosis in hepatocellular carcinoma.

Authors:  Qiutong Guan; Jing Pan; Ninghui Ren; Chu Qiao; Minjie Wei; Zhenhua Li
Journal:  Front Cell Dev Biol       Date:  2022-09-02

6.  Secretory Clusterin Mediates Oxaliplatin Resistance via the Gadd45a/PI3K/Akt Signaling Pathway in Hepatocellular Carcinoma.

Authors:  Xin Wang; Fang Zou; Jingtao Zhong; Longtao Yue; Fuhai Wang; Honglong Wei; Guangsheng Yang; Tao Jin; Xiaofeng Dong; Jie Li; Peng Xiu
Journal:  J Cancer       Date:  2018-04-06       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.